HCM
AXSM icon

Highlander Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Highlander Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$26K – 659
2019
Q2 		$26K Buy
+1,000
New +$20K 0.02% 413

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Highlander Capital Management's AXSM Position: Q3 2019 in Review

Highlander Capital Management sold out of Axsome Therapeutics (AXSM) in Q3 2019, closing a stake of 1,000 shares — an estimated $26K sold.

Highlander Capital Management first reported a position in AXSM in Q2 2019 and held it in 1 quarter. The position peaked at $26K in Q2 2019. 111 funds tracked by Wall St. Rank hold AXSM as of Q3 2019.

  • Highlander Capital Management reported no remaining Axsome Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Highlander Capital Management sold 1,000 Axsome Therapeutics shares in Q3 2019, an estimated $26K.
  • Highlander Capital Management first reported a position in Axsome Therapeutics in Q2 2019 and held it in 1 quarter.
  • Highlander Capital Management's Axsome Therapeutics position peaked at $26K in Q2 2019.
  • 111 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2019.

Based on Highlander Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.